guidelines on sudden cardiac death 2015 (tf07) - task force · - edwards lifesciences : speaker...
TRANSCRIPT
Blom Nico Nothing to be declared (2012-2013-2014-2015)
Blomstrom-Lundqvist Carina
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Sanofi Aventis : AF (2012)
- Bayer : atrial fibrillation (2013)
- Pfizer : anticoagulation (2014)
- Sanofi Aventis : anticoagulation (2014)
- Bayer : anticoagulation (2014-2015)
- Bristol Myers Squibb : anticoagulation (2015)
- Boston Scientific : Arrhythmias (2015)
- Medtronic : catheter ablation of atrial fibrillation (2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Medtronic : AF (2012-2013-2014)
- Biotronik : Arrhythmia (2012-2013-2014)
- Octopus : Arrhythmia (2015)
- Medtronic : Atrial fibrillation (2015)
D - Research funding (departmental or institutional).- Medtronic : AF (2012-2013-2014)
- Biotronik : Arrhythmias (2012-2013-2014)
- Octopus : Arrhythmias (2015)
- Medtronic : Atrial fibrillation (2015)
Borggrefe Martin A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- St Jude Medical : Catheters (2012)
- Bard : Catheters (2012)
- VEST : Medical devices (2012)
27/08/2015
Guidelines on Sudden Cardiac Death 2015 (TF07) - Task Force
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
1/46
Borggrefe Martin - Boehringer-Ingelheim : Drugs (2012-2013-2014-2015)
- Sanofi Aventis : Drugs (2012-2013-2014-2015)
- Bayer Healthcare : Drugs (2012-2013-2014-2015)
- Medtronic : Medical devices (2012-2013-2014-2015)
- Impulse Dynamics : Medical devices (2012-2013-2014-2015)
- Boston Scientific : Stents, Catheter (2012-2013-2014-2015)
- St Jude Medical : Catheters, ICD (2013-2014-2015)
- Novartis : Drugs (2013-2014-2015)
- Zoll Medical : Medical devices (2013-2014-2015)
- Daiichi Sankyo : drugs (2014-2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- VEST : Medical devices (2012)
- Boehringer-Ingelheim : Drugs (2012-2013-2014-2015)
- Pfizer : Drugs (2012-2013-2014-2015)
- Sanofi Aventis : Drugs (2012-2013-2014-2015)
- Medtronic : Medical devices (2012-2013-2014-2015)
- St Jude Medical : Medical devices (2012-2013-2014-2015)
- Impulse Dynamics : Medical devices (2012-2013-2014-2015)
- Zoll Medical : Medical devices (2013-2014-2015)
C - Receipt of royalties for intellectual property.- Thieme Verlag : Author ship (2012)
- Thieme Verlag : Authorship (2013-2014-2015)
Camm John A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Forest Pharmaceuticals : Azimilide (2012)
27/08/2015
Guidelines on Sudden Cardiac Death 2015 (TF07) - Task Force
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
2/46
Camm John - Cameron Health : All (2012-2013)
- Merck Sharp & Dohme : DSMB - Ablation (2012-2013)
- AGA : DSMB - several (2012-2013)
- Johnson & Johnson : Apixaban (2012-2013-2014)
- Bristol Myers Squibb : DSMB (2012-2013-2014)
- ChanRx : antiarhhythmic drug (2012-2013-2014-2015)
- Wiley Blackwell : Clinical Cardiology (2012-2013-2014-2015)
- Boehringer-Ingelheim : Dabigatran (2012-2013-2014-2015)
- Biotronik : DSMB - Ablation (2012-2013-2014-2015)
- Novartis : DSMB - several (2012-2013-2014-2015)
- Infobionics : ECG monitoring (2012-2013-2014-2015)
- Oxford University Press : Europace and ESC textbook (2012-2013-2014-2015)
- GlaxoSmithKline : General Advice (2012-2013-2014-2015)
- Servier : Multiple products (2012-2013-2014-2015)
- Sanofi Aventis : Multiple products (2012-2013-2014-2015)
- Menarini : Ranolazine (2012-2013-2014-2015)
- Gilead : Ranolazine (2012-2013-2014-2015)
- Bayer : Rivaroxaban (2012-2013-2014-2015)
- Medtronic : Subcutaneous monitoring (2012-2013-2014-2015)
- Bristol Myers Squibb : Apixaban (2015)
- BioControl Medical : DSMB (2015)
- Daiichi Sankyo : Edoxaban (2015)
27/08/2015
Guidelines on Sudden Cardiac Death 2015 (TF07) - Task Force
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
3/46
Camm John - Johnson & Johnson : Rivaroxaban (2015)
D - Research funding (departmental or institutional).- Sanofi Aventis : Edoxaban (2012)
- Servier : Antiarrhythmic drug (2012-2013-2014-2015)
- BMS/Pfizer : Apixaban (2012-2013-2014-2015)
- Daiichi Sankyo : Edoxaban (2012-2013-2014-2015)
- Richmond Pharmacology : Many phase 1 NCEs (2012-2013-2014-2015)
Elliott Perry Mark A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Shire HGT : Enzyme replacement therapy Fabry disease (2012-2013-2014-2015)
- Genzyme : Enzyme replacement therapy Fabry disease (2012-2013-2014-2015)
- Pfizer : Treatment for TTR amyloidosis (2012-2013-2014-2015)
- MyoKardia : Mutation guided therapies in cardiomyopathy (2014-2015)
D - Research funding (departmental or institutional).- Genzyme : Cardiac magenetic resonance imaging in HCM (2012-2013-2014-2015)
- Shire HGT : Clinical characterisation of Anderson-Fabry Disease (2012-2013-2014-2015)
- National Institute for Health and Clinical Excellence : Genetics of hypertrophic cardiomyopathy (2012-2013-2014-2015)
- British Heart Foundation : Hypertrophic cardiomyopathy (2012-2013-2014-2015)
Fitzsimons Donna Nothing to be declared (2012-2013-2015)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Amgen : FH Tratment options (2014)
Hatala Robert A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Abbott : drugs (2012)
- Bayer : drugs (2012)
- Boehringer-Ingelheim : drugs (2012)
- Pfizer : drugs (2012)
27/08/2015
Guidelines on Sudden Cardiac Death 2015 (TF07) - Task Force
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
4/46
Hatala Robert - Servier : drugs (2012)
- Bayer : antithrombotic therapy (2013)
- Abbott : cardiovascular drugs (2013)
- Sanofi Aventis : cardiovascular drugs (2013)
- Boston Scientific : CRM (2013)
- St Jude Medical : CRM (2013)
- Biotronik : CRM (2013)
- Boehringer-Ingelheim : antithrombotic therapy (2013-2014)
- Pfizer : cardiovascular drugs (2013-2014-2015)
- Servier : cardiovascular drugs (2013-2014-2015)
- Medtronic : CRM (2013-2014-2015)
- Bayer AG : antithrombotic therapy (2014-2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- St Jude Medical : CRM (2012)
- Medtronic : CRM (2012-2013-2014-2015)
- Biotronik : CRM (2012-2013-2014-2015)
D - Research funding (departmental or institutional).- Medtronic : CRM (2012-2013-2014-2015)
- Biotronik : CRM (2013)
Hindricks Gerhard A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Stereotaxis : catheter ablation (2012)
- Biosense Webster : catheter ablation (2012)
- Medtronic : Pacemaker (2012)
- St Jude Medical : Pacemaker, catheter ablation (2012)
27/08/2015
Guidelines on Sudden Cardiac Death 2015 (TF07) - Task Force
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
5/46
Hindricks Gerhard - Biotronik : Pacemaker, catheter ablation (2012-2013)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Stereotaxis : catheter ablation (2012)
- Biosense Webster : catheter ablation (2012)
- Medtronic : Pacemaker (2012)
- Biotronik : Pacemaker, catheter ablation (2012)
- St Jude Medical : Pacemaker, catheter ablation (2012-2013)
- Boston Scientific : IC, CRT, Catheter Ablation (2014-2015)
- Biotronik : ICD, CRT (2014-2015)
- St Jude Medical : ICD, CRT, Catheter Ablation (2014-2015)
C - Receipt of royalties for intellectual property.- Biosense Webster : Pacemaker, catheter ablation (2013)
D - Research funding (departmental or institutional).- St Jude Medical : catheter ablation, pacemaker (2012)
- Biotronik : catheter ablation, pacemaker (2012)
- Stereotaxis : Pacemaker, catheter ablation (2013)
- Daiichi Sankyo : atrial fibrillation, anticoagulation (2014-2015)
- Boston Scientific : ICD, CRT, Catheter Ablation (2014-2015)
- St Jude Medical : ICD, CRT, Catheter Ablation (2014-2015)
- Biotronik : ICD, CRT, Catheter Ablation (2014-2015)
- Zoll Medical : wearable ICD (2014-2015)
E - Research funding (personal).- Medtronic : Pacemaker, catheter ablation (2013)
Kirchhof Paulus A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Otsuka Pharmaceuticals Development and Commercialization (consultancy) : cardiovascular (2012-2013)
27/08/2015
Guidelines on Sudden Cardiac Death 2015 (TF07) - Task Force
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
6/46
Kirchhof Paulus - Boehringer-Ingelheim : cardiovascular (2012-2013-2014-2015)
- Daiichi Sankyo : cardiovascular (2012-2013-2014-2015)
- Medtronic : cardiovascular (2012-2013-2014-2015)
- Pfizer : cardiovascular (2012-2013-2014-2015)
- St Jude Medical : cardiovascular (2012-2013-2014-2015)
- Sanofi Aventis : cardiovascular (2012-2013-2014-2015)
- Meda pharma : cardiovascular (2012-2013-2014-2015)
- Bristol Myers Squibb : cardiovascular (2012-2013-2014-2015)
- Merck Sharp & Dohme : cardiovascular (2012-2013-2014-2015)
- Medscape : cardiovascular (2014-2015)
- Bayer Healthcare : cardiovascular (2015)
- Correvio : cardiovascular (2015)
- Remedica : cardiovascular (2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Portola Pharmaceuticals : cardiovascular (2012)
- Boehringer-Ingelheim : cardiovascular (2012-2013)
- Bayer Healthcare : cardiovascular (2012-2013)
- BMS / Pfizer alliance : cardiovascular (2012-2013)
- Gilead : cardiovascular (2013)
D - Research funding (departmental or institutional).- St Jude Medical : cardiovascular (2012-2013-2014-2015)
- Sanofi Aventis : cardiovascular (2012-2013-2014-2015)
- Meda pharma : cardiovascular (2012-2013-2014-2015)
27/08/2015
Guidelines on Sudden Cardiac Death 2015 (TF07) - Task Force
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
7/46
Kirchhof Paulus - Daiichi Sankyo : cardiovascular (2014-2015)
- British Heart Foundation : cardiovascular (2014-2015)
- BMS / Pfizer alliance : cardiovascular (2014-2015)
- Leducq Foundation : cardiovascular (2014-2015)
- European Union FP7 : cardiovascular (2014-2015)
- European Union horizon2020 : cardiovascular (2014-2015)
- German Centre for Heart Research (DZHK, funded by German Ministry of Education and Research) : cardiovascular (2014-2015)
Kjeldsen Keld Per Nothing to be declared (2012-2013-2014-2015)
Kuck Karl-Heinz A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Medtronic : Speaker Fees, Honorary, Consultancy (2012)
- Abbott Vascular : Speaker Fees, Honorary, Consultancy (2012)
- Cordis : Speaker Fees, Honorary, Consultancy (2012)
- St. Jude : Speaker Fees, Honorary, Consultancy (2012)
- CCM- Impulse Dynamics : Speaker Fees, Honorary, Consultancy (2012)
- Biosense Webster : Speaker Fees, Honorary, Consultancy (2012-2013-2014)
- Edwards Lifesciences : Speaker Fees, Honorary, Consultancy (2012-2013-2014-2015)
- Stereotaxis : Speaker Fees, Honorary, Consultancy (2013-2014-2015)
- Medtronic Foundation : Speaker Fees, Honorary, Consultancy (2013-2014-2015)
- St. Jude Medical : Speaker Fees, Honorary, Consultancy (2013-2014-2015)
- Biosense Webstser : Speaker Fees, Honorary, Consutlancy (2015)
Madrid Antonio Nothing to be declared (2014-2015)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- St Jude Medical : RESYNCHRONIZATION (2012-2013)
27/08/2015
Guidelines on Sudden Cardiac Death 2015 (TF07) - Task Force
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
8/46
Madrid Antonio B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Medtronic : DEFIBRILLATOR (2012-2013)
Mazzanti Andrea Nothing to be declared (2012-2013-2014-2015)
Nikolaou Nikolaos B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Sanofi Aventis : Antiplatelet drugs (2012-2013)
- Amgen : Drugs for hyperlipidemia (2012-2013-2014-2015)
Norekval Tone Merete Nothing to be declared (2012-2013-2014-2015)
Priori Silvia Giuliana A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boston Scientific : CRM (2012)
- Biotronik : CRM (2012)
- Transgenomic : Genetics (2012)
- Medtronic : CRM (2012-2013)
- Medtronic : Cardiac Rhythm Management (2014-2015)
- Gilead Inc : antiarrhythmic drugs (2015)
- Cardiogen : Genetics (2015)
- GE Healthcare : Health products (2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boston Scientific : CRM (2013)
- Boston Scientific : Cardiac Rhythm Management (2014-2015)
D - Research funding (departmental or institutional).- Gilead : antiarrhythmic drugs (2014-2015)
- Boston Scientific : epidemiology of Brugada Syndrome (2014-2015)
Spaulding Christian A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Acute coronary syndrome (2012-2013)
- Lilly : acute coronary syndromes (2012-2013)
- Iroko Cardio : acute coronary syndromes (2012-2013)
27/08/2015
Guidelines on Sudden Cardiac Death 2015 (TF07) - Task Force
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
9/46
Spaulding Christian - Abiomed : cardiac support (2012-2013)
- Medtronic : coronary stents (2012-2013)
- Cordis : radial approach (2012-2013)
- Medpass : Expert for regulatory and medical issues (2013)
- Servier : Heart failure (2013)
- Abiomed : Cardiac assist (2014)
- Zoll Medical : Defibrillators (2014)
- Servier : Teaching (2014)
- The Medicines Company : Anticoagulants (2014-2015)
- Daiichi Sankyo : Antiplatelet therapy (2014-2015)
- Astra Zeneca : Antiplatelet treatment (2014-2015)
- Wallstreet Institute : Financing of start ups (2014-2015)
- Lilly : GP IIb IIIa inhibitor (2014-2015)
- GE Healthcare : Imaging (2014-2015)
- Medtronic : Interventional cardiology (2014-2015)
- Biosensors : Stents (2014-2015)
- Bayer Healthcare : Teaching (2014-2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Biomatrix : coronary stents (2012-2013)
- Inspire MD : Coronary stents (2013)
D - Research funding (departmental or institutional).- INSERM : cardiac arrest (2012-2013)
- CERC : Trials (2014-2015)
27/08/2015
Guidelines on Sudden Cardiac Death 2015 (TF07) - Task Force
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
10/46
van Veldhuisen Dirk A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- BG medicine : Diagnostics (2012)
- BioControl : Heart failure devices (2012)
- Johnson & Johnson : Heart failure drugs (2012)
- Vifor International : Intravenous Iron (2012)
- Sorbent : K extruder (2012)
- Amgen : ESA (2012-2013)
- St Jude Medical : HF devices (2013)
- BioControl : HF devices (2013)
- Novartis : HF drugs (2013)
- Johnson & Johnson : HF drugs (2013)
- Vifor International : iv iron (2013)
- Sorbent : K+extruder (2013)
- Novartis : heart failure (2014-2015)
- Cardiorentis : heart failure (2014-2015)
- Johnson & Johnson : heart failure (2014-2015)
- Vifor International : heart failure (2014-2015)
- BioControl : Heart failure (2014-2015)
D - Research funding (departmental or institutional).- St Jude Medical : arrhythmias (2014-2015)
27/08/2015
Guidelines on Sudden Cardiac Death 2015 (TF07) - Task Force
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
11/46
Abdrakhmanov Ayan Nothing to be declared (2013-2014-2015)
Abou El-Maaty Mervat Nothing to be declared (2013-2014-2015)
Agewall Stefan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Böhringer Ingelheim : Anticoagulatn treatment (2013)
- Roche Diagnostics : Cardiac markers (2013)
- Orion : Heart failure (2013)
- Pfizer : Lipids (2013)
- Sanofi Aventis : Lipids (2013)
- Siemens Healthcare : Markers (2013)
- Astra Zeneca : Platelet inhibition (2013-2014-2015)
- Thermo Fischer Scientific : Cardiac markers (2014-2015)
Antoniades Loizos Nothing to be declared (2013-2014-2015)
Arenal Maiz Angel A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Biosense Webster : Ablation (2013-2014-2015)
- Boston Scientific : ICD and Ablation (2013-2014-2015)
- Medtronic : ICD and Ablation (2013-2014-2015)
D - Research funding (departmental or institutional).- Biosense Webster : Ablation (2013-2014-2015)
Baron Esquivias Gonzalo A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer : Anticoagulation (2013-2014-2015)
- Boehringer-Ingelheim : Anticoagulation (2013-2014-2015)
- Daiichi Sankyo : Anticoagulation (2013-2014-2015)
- Pfizer : Anticoagulation (2013-2014-2015)
- Menarini : Ischemic disease (2015)
27/08/2015
Guidelines on Sudden Cardiac Death 2015 (TF07) - Document Reviewers
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
12/46
Baron Esquivias Gonzalo - Laboratorios Rovi : Ivabradine (2015)
D - Research funding (departmental or institutional).- Biotronik : Vasovagal syncope & Pacing (2013)
- Bayer : Anticoagulation (2015)
Benlamin Hisham Nothing to be declared (2013-2014-2015)
Boriani Giuseppe A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boston Scientific : Pacemaker, cardioverter defibrillators (2013-2014-2015)
- Medtronic : Pacemaker, cardioverter defibrillators (2013-2014-2015)
- St.Jude : Pacemaker, cardioverter defibrillators (2014-2015)
- Boehringer-Ingelheim : Anticoagulants (2015)
- Biotronik : Pacemaker, cardioverter defibrillators (2015)
Budts Werner A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Occlutech : PFO and ASD closure (2014-2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Novartis : Hypertension (2013)
- Servier : Atherosclerosis (2013-2014-2015)
- St Jude Medical : Interventional cardiology (2013-2014-2015)
- Occlutech : Interventional cardiology (2013-2014-2015)
- Astra Zeneca : Lipids (2013-2014-2015)
- Pfizer : Lipids (2013-2014-2015)
- Actelion : Pulmonary hypertension (2013-2014-2015)
- Boston Scientific : LAA closure (2014-2015)
- Medtronic : Ceraflex - Venus valve (2015)
D - Research funding (departmental or institutional).- Actelion : Pulmonary hypertension (2013-2014)
27/08/2015
Guidelines on Sudden Cardiac Death 2015 (TF07) - Document Reviewers
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
13/46
Bueno Hector A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- BMS/Pfizer : Apixaban (2013)
- Roche Pharma : Dalcetrapib (2013)
- Novartis : Relaxin (2013)
- Bayer Healthcare : Aspirin, rivaroxaban (2013-2014-2015)
- Sanofi Aventis : Clopidogrel (2013-2014-2015)
- Daiichi Sankyo : Prasugrel (2013-2014-2015)
- Eli Lilly : Prasugrel (2013-2014-2015)
- Astra Zeneca : Ticagrelor (2013-2014-2015)
- Novartis : Serelaxin (2014)
- Pfizer : Apixaban (2014-2015)
- Bristol Myers Squibb : Apixaban (2014-2015)
- Servier : ivabradine (2014-2015)
- Menarini : Ranolazine (2014-2015)
- Abbott : Absorb stent (2015)
- Novartis : Serelaxin, ACZ696 (2015)
- Ferrer Internacional : Trinomia (polypill) (2015)
D - Research funding (departmental or institutional).- Astra Zeneca : Funding of TAN-SNIP observational study. No drugs involved (2015)
E - Research funding (personal).- Astra Zeneca : Ticagrelor (2013-2014-2015)
Capodanno Davide A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Eli Lilly/Daiichi Sankyo : Antithrombotic drugs (2013-2014)
- Astra Zeneca : Antithrombotic drugs (2013-2014-2015)
27/08/2015
Guidelines on Sudden Cardiac Death 2015 (TF07) - Document Reviewers
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
14/46
Capodanno Davide - Bayer : Antithrombotic drugs (2014)
- Abbott Vascular : Mitral valve repair (2014)
- Daiichi Sankyo : Antithrombotic drugs (2015)
Carerj Scipione Nothing to be declared (2013-2014-2015)
Chaib Ali Nothing to be declared (2013)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : hypertension and heart failure (2014-2015)
- Boehringer-Ingelheim : new anticoagulants (2014-2015)
Chettaoui Rafik Nothing to be declared (2013-2014-2015)
Crespo-Leiro Maria G A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : ivabradine (2013)
- Novartis : relaxine (2013)
- Roche Pharma : mycophenolate mofetil (2013-2014)
- Astellas : tacrolimus (2013-2014)
- Diaxonhit : AlloMap (2014)
- Novartis : relaxine, LCZ696 (2014)
- Bioventrix : Ventricular restauration technology (2014)
- Novartis : Heart Failure (2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : ivabradine (clinical trial) (2013-2014)
- Novartis : relaxin (clinical trial) and LCZ 696 (clinical trial) (2013-2014)
- Novartis : Heart Failure (2015)
Czerny Martin Nothing to be declared (2013-2014-2015)
Deaton M Christi Nothing to be declared (2013)
27/08/2015
Guidelines on Sudden Cardiac Death 2015 (TF07) - Document Reviewers
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
15/46
Deaton M Christi A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer : none (2014-2015)
- Boehringer-Ingelheim : none (2014-2015)
- Daiichi Sankyo : none (2014-2015)
- Sanofi Aventis : none (2014-2015)
Deftereos Spyridon Nothing to be declared (2013-2014-2015)
Della Bella Paolo A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- St Jude Medical : Cardiac electrophysiology (2013-2014)
- Biotronik : Cardiac electrophysiology (2013-2014)
- Biosense Webster : Cardiac electrophysiology (2013-2014)
- Boston Scientific : Electromedical (2015)
- St JuJude Medical : Electromedical (2015)
D - Research funding (departmental or institutional).- Boston Scientific : Cardiac electrophysiology (2013-2014)
- Medtronic : Cardiac electrophysiology (2013-2014)
- St Jude Medical : Cardiac electrophysiology (2013-2014)
- Biotronik : Cardiac electrophysiology (2013-2014)
- Biosense Webster : Cardiac electrophysiology (2013-2014)
- Boston Scientific : Electromedical (2015)
- St Jude Medical : Electromedical (2015)
- Biosense : Electromedical (2015)
Demir Mesut Nothing to be declared (2013-2014-2015)
Dobrev Dobromir A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Sanofi Aventis : antiarrhythmic drugs (2013)
27/08/2015
Guidelines on Sudden Cardiac Death 2015 (TF07) - Document Reviewers
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
16/46
Dobrev Dobromir - Daiichi-Sankyo : novel anticoagulans (2013)
- Daiichi Sankyo : Honoraria (2014)
- Bayer Vital : Honoraria (2014)
- OMEICOS : Honoraria for consultancy services (2015)
- Daiichi Sankyo : Honoraria for educational lectures (2015)
- Servier : Honoraria for educational lectures (2015)
- Bayer Vital : Honoraria for educational lectures (2015)
Duncan Edward Nothing to be declared (2013-2014-2015)
Eckardt Lars A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Sanofi Aventis : Antiarrhythmic drugs (2013)
- Bayer : Anticoagulation (2013)
- Boehringer-Ingelheim : Anticoagulation (2013)
- Daiichi Sankyo : Anticoagulation (2013)
- Pfizer : Anticoagulation (2013)
- Bristol Myers Squibb : Anticoagulation (2013)
- Johnson & Johnson : Electrophysiology (2013)
- Boston Scientific : Electrophysiology (2013-2014-2015)
- Medtronic : Electrophysiology (2013-2014-2015)
- St Jude Medical : Electrophysiology (2013-2014-2015)
- Biotronik : Electrophysiology (2013-2014-2015)
- Boehringer-Ingelheim : Electrophysiology (2014-2015)
- Daiichi Sankyo : Electrophysiology (2014-2015)
- Pfizer : Electrophysiology (2014-2015)
27/08/2015
Guidelines on Sudden Cardiac Death 2015 (TF07) - Document Reviewers
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
17/46
Eckardt Lars - Sanofi Aventis : Electrophysiology (2014-2015)
- Bristol Myers Squibb : Electrophysiology (2014-2015)
- Bayer AG : Electrophysiology (2014-2015)
- Johson & Johnson : Electrophysiology (2014-2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Biotronik : Electrophysiology (2014-2015)
- Osypka : Electrophysiology (2014-2015)
D - Research funding (departmental or institutional).- Osypka GmbH : Electrophysiology (2014-2015)
Erol Cetin A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Hypertension (2013-2014-2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Menarini : Hypertension (2013-2014-2015)
Etsadashvili Kakhaber A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Perindopril, Ivabradine, (2013-2014-2015)
Galderisi Maurizio Nothing to be declared (2013-2014-2015)
Geller Laszlo A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- St Jude Medical : AF ablation (2013)
- Johnson & Johnson : catheter ablation of VTs, catheter ablation of AF, resynchronization therapy (2013)
- Biotronik : pacemaker therapy, resynchronization therapy (2013)
- Medtronic : Arrhythmia (2014-2015)
- St Jude Medical : Arrhythmia (2014-2015)
- Biotronik : Arrhythmia (2014-2015)
- Johnson & Johnson : Arrhythmia (2014-2015)
- Boston Scientific : Arrhythmia (2015)
27/08/2015
Guidelines on Sudden Cardiac Death 2015 (TF07) - Document Reviewers
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
18/46
Geller Laszlo B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Medtronic : Arrhythmia (2014-2015)
- St Jude Medical : Arrhythmia (2014-2015)
- Biotronik : Arrhythmia (2014-2015)
- Johnson & Johnson : Arrhythmia (2014-2015)
Gizurarson Sigfus Nothing to be declared (2013-2014)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Pfizer : NOAC (2015)
Gorenek Bulent Nothing to be declared (2013-2014-2015)
Goronja Boris A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : arrhythmias (2013)
- GlaxoSmithKline : hypertension (2013)
- Krka Pharma : hypertension (2013)
- Bayer : speaker fee- NOAC drug (2013-2014)
- Medtronic : Cardiac Pacing, SCD, Syncope (2013-2014-2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Medtronic : Panorama 2 trial (2013-2014-2015)
- PLIVA : speaker fee- art. hypertension (2014-2015)
Groben Laurent A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Daiichi Sankyo : Edoxaban - Board from 11/14 (2013-2014-2015)
Haim Moti A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boehringer-Ingelheim : NOACS (2013-2014-2015)
- Pfizer : NOACS (2013-2014-2015)
- Bayer : noacs (2015)
D - Research funding (departmental or institutional).- Boston Scientific : ICD LEADS (2013-2014)
27/08/2015
Guidelines on Sudden Cardiac Death 2015 (TF07) - Document Reviewers
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
19/46
Haim Moti - Pfizer : Atrial Fibrillation (2015)
Hedman Antti A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Cardiome UK : Antiarrhythmics (2013-2014-2015)
- Boehringer-Ingelheim : Anticoagulants (2013-2014-2015)
- Bristol Myers Squibb : Anticoagulants (2013-2014-2015)
- Johnson & Johnson : Electrophysiology (2013-2014-2015)
Hlivak Peter A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Abbott : speaker fees: ECG training (2013-2014)
- Bayer : speaker fees: SPAF - thromboprophylaxis in AF (2013-2014-2015)
- Pfizer : speaker fees: SPAF - thromboprophylaxis in AF (2013-2014-2015)
- Abbott : speaker fees: antiarrhytmic therapy /role of propafenone in AF treatment/ (2015)
D - Research funding (departmental or institutional).- Medtronic : monitoring of AF, ILR (2013)
Jensen-Urstad Mats A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Medtronic : Electrophysiology (2013-2014-2015)
- Johnson & Johnson : Electrophysiology (2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Medtronic : Electrophysiology (2014-2015)
D - Research funding (departmental or institutional).- St Jude Medical : Electrophysiology (2013)
- Medtronic : Electrophysiology (2013-2014-2015)
Kalejs Oskars A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Cardiovascular Pharmacotherapy (2013-2014-2015)
- Abbott : Cardiovascular Pharmacotherapy. (2013-2014-2015)
- Boehringer-Ingelheim : Cardiovascular Pharmacotherapy. (2013-2014-2015)
- Novartis : Cardiovascular Pharmacotherapy. (2013-2014-2015)
27/08/2015
Guidelines on Sudden Cardiac Death 2015 (TF07) - Document Reviewers
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
20/46
Kalejs Oskars - Servier : Cardiovascular Pharmacotherapy. (2013-2014-2015)
- Bayer AG : Cardiovascular Pharmacotherapy. (2013-2014-2015)
- Pfizer : Cardiovascular Pharmacotherapy (2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Biosense Webster : Treatment of Atrial Fibrillation, Catheter Ablation (2013-2014-2015)
D - Research funding (departmental or institutional).- Latvian Research Institute of Cardiology : Treatment of Heart Failure (2013-2014-2015)
Kamcevska-Dobrkovic Lidija
Nothing to be declared (2013-2014-2015)
Kampus Priit A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Berlin Chemie AG : Central blood pressure and betablockers (2013-2014-2015)
D - Research funding (departmental or institutional).- Estonian Research Council : Arterial stiffness and blood pressure (2013-2014-2015)
- Berlin Chemie AG : Central blood pressure and betablockers (2013-2014-2015)
Kautzner Josef A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Abbott : drugs (2013)
- GE Healthcare : X ray, echocardiography, imaging software (2013)
- Hansen Medical : robotic technology for ablation (2013-2014)
- Siemens Healthcare : X ray, echocardiography, imaging software (2013-2014)
- Biosense Webster : catheters, mapping system (2013-2014-2015)
- Bayer : drugs (2013-2014-2015)
- Boehringer-Ingelheim : drugs (2013-2014-2015)
- Boston Scientific : pacemakers, ICDs (2013-2014-2015)
- Medtronic : pacemakers, ICDs (2013-2014-2015)
- Biotronik : pacemakers, ICDs, catheters (2013-2014-2015)
- St Jude Medical : pacemakers, ICDs, catheters, mapping system (2013-2014-2015)
27/08/2015
Guidelines on Sudden Cardiac Death 2015 (TF07) - Document Reviewers
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
21/46
Kautzner Josef - Daiichi Sankyo : drugs (2014-2015)
- Resmed : ventilators, diagnostics (2015)
D - Research funding (departmental or institutional).- Endosense : catheters (2013)
- Biosense Webster : catheters, mapping system (2013-2014-2015)
- Boston Scientific : pacemakers, ICDs (2013-2014-2015)
- Biotronik : pacemakers, ICDs, catheters (2013-2014-2015)
- Daiichi Sankyo : drugs (2014-2015)
Keane David Tj A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- lake regional medical : arrhythmias - consultancy (2013-2014-2015)
- Johnson & Johnson : arrhythmias - speaker (2013-2014-2015)
C - Receipt of royalties for intellectual property.- Medtronic : Ablation - investigational (2013-2014-2015)
Kolh Philippe H A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- B.Braun : Surgical instruments (2013-2014)
- Astra Zeneca : Antiplatelet agents (2013-2014-2015)
D - Research funding (departmental or institutional).- St Jude Medical : Cardiac valves (2013)
- Boston Scientific : Coronary stents (2013)
- Siemens Healthcare : Medical imaging (2013)
- Johnson & Johnson : Thoracoscopic devices (2013)
- Edwards Lifesciences : Cardiac valves (2013-2014-2015)
- Medtronic : Cardiac valves (2013-2014-2015)
Kriebel Thomas A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- AOP Orphan Pharmaceuticals : Consultant (2013)
- AOP Orphan Pharmaceuticalsl : Product (2014-2015)
27/08/2015
Guidelines on Sudden Cardiac Death 2015 (TF07) - Document Reviewers
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
22/46
Kriebel Thomas B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Medtronic : EcG course (2014)
- St Jude Medical : Ecg course (2014)
- Nestle : Ecg course (2014-2015)
- Mortara : ECG course (2014-2015)
- Nestle : symposium (2015)
Lambiase Pier A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boston Scientific : Devices (2013-2014-2015)
D - Research funding (departmental or institutional).- Medtronic : Devices (2013-2014-2015)
- Boston Scientific : Devices/Electrophysiology (2013-2014-2015)
- St Jude Medical : Electrophysiology (2013-2014-2015)
- Acutus : Electrophysiology (2013-2014-2015)
Lancellotti Patrizio A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Heart Failure (2013)
- Abbott : MitraClip (2013)
- Menarini : nebivolol (2014)
- St Jude Medical : Heart Failure (2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astrazeneca : Dyslipidemia (2013)
- Boston Scientific : CRT (2014)
- Servier : procoralan (2014)
- Daiichi Sankyo : Teaching course on imaging (2015)
D - Research funding (departmental or institutional).- Actelion : Pulmonary Hypertension (2013)
27/08/2015
Guidelines on Sudden Cardiac Death 2015 (TF07) - Document Reviewers
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
23/46
Lane Deirdre A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bristol Myers Squibb/Pfizer : Atrial fibrillation (2013)
- Bayer : Atrial fibrillation (2014)
- Boehringer-Ingelheim : Atrial fibrillation (2014)
- Bristol Myers Squibb : Atrial fibrillation (2014-2015)
- Pfizer : Atrial fibrillation (2015)
D - Research funding (departmental or institutional).- Bayer Healthcare : Atrial fibrillation (2013)
- Boehringer-Ingelheim : Atrial fibrillation (2013-2014-2015)
- Bristol Myers Squibb : Atrial fibrillation (2014-2015)
Lang Irene Marthe A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Actelion : Bosentan (2013)
- Cordis : Cypher (2013)
- Astra Zeneca : Rosiglitazone (2013)
- Lilly : Tadalafil, ReoPro (2013)
- Merck Sharp & Dohme : Vernakalant (2013)
- GlaxoSmithKline : Ambrisentan (2013-2014-2015)
- Boehringer-Ingelheim : Dabigatran (2013-2014-2015)
- Spectranetics : Laser (2013-2014-2015)
- Servier : Procoralan (2013-2014-2015)
- Medtronic : Resolute (2013-2014-2015)
- Bayer Healthcare : Riociguat (2013-2014-2015)
- Boston Scientific : stents (2013-2014-2015)
- Biotronik : stents (2013-2014-2015)
27/08/2015
Guidelines on Sudden Cardiac Death 2015 (TF07) - Document Reviewers
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
24/46
Lang Irene Marthe - United Therapeutics : Treprostinil (2013-2014-2015)
- Actelion : Opsumit (2014-2015)
- Daiichi Sankyo : Prasugrel (2014-2015)
- Astra Zeneca : Rosuvastatin (2014-2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Clarify Registry (2013-2014-2015)
- Bayer Healthcare : CTEPH Academy Vienna (2015)
D - Research funding (departmental or institutional).- Actelion : Bosentan (2013-2014-2015)
- Bayer : research funding (2014-2015)
Larsen Jacob Moesgaard B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Pfizer : one speakers fee (<300 Euro) payed to my institution (2015)
E - Research funding (personal).- Danish Heart Foundation : Founding of PhD-study on ICD-leads (2013)
- Danish Heart Foundation : ICD leads (2014)
Lenarczyk Radoslaw A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boehringer-Ingelheim : Producer of drugs (2013-2014-2015)
- Medtronic : Producer of pacemakers, ICDs, CRT-devices (2013-2014-2015)
- St Jude Medical : Producer of pacemakers, ICDs, CRT-devices (2013-2014-2015)
- Biotronik : Producer of pacemakers, ICDs, CRT-devices (2013-2014-2015)
Lip Gregory Y H A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astellas : atrial fibrillation, thrombosis (2013)
- Biotronik : atrial fibrillation (2013-2014-2015)
- Boehringer-Ingelheim : atrial fibrillation, thrombosis (2013-2014-2015)
- Daiichi Sankyo : atrial fibrillation, thrombosis (2013-2014-2015)
- Pfizer : atrial fibrillation, thrombosis (2013-2014-2015)
27/08/2015
Guidelines on Sudden Cardiac Death 2015 (TF07) - Document Reviewers
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
25/46
Lip Gregory Y H - Bayer Healthcare : atrial fibrillation, thrombosis (2013-2014-2015)
- Bristol Myers Squibb : atrial fibrillation, thrombosis (2013-2014-2015)
- Medtronic : atrial fibrillation (2014-2015)
- Roche Diagnostics : anticoagulation (2015)
D - Research funding (departmental or institutional).- Bayer : atrial fibrillation, thrombosis (2013)
- Daiichi Sankyo : atrial fibrillation, thrombosis (2014-2015)
Mairesse Georges H A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer Healthcare : NOAC (2013-2014)
- Boehringer-Ingelheim : NOAC (2013-2014-2015)
- Daiichi Sankyo : NOAC (2013-2014-2015)
- Bristol Myers Squibb : NOAC (2013-2014-2015)
- Medtronic : pacemakers (2013-2014-2015)
- Johnson & Johnson : AF (2014-2015)
- Servier : If inhibitors (2014-2015)
- Sorin Group : pacemakers (2014-2015)
- Biotronik : pacemakers - telemonitoring (2014-2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Sanofi Aventis : Dronédarone (2013)
- Daiichi Sankyo : NOAC (2013)
- Medtronic : Pacemaker (2013)
- Bristol Myers Squibb : NOAC (2013-2014-2015)
- Sorin Group : Pacemaker (2013-2014-2015)
- St Jude Medical : Pacemaker (2013-2014-2015)
27/08/2015
Guidelines on Sudden Cardiac Death 2015 (TF07) - Document Reviewers
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
26/46
Mairesse Georges H - Boehringer-Ingelheim : NOAC (2014-2015)
- Biotronik : pacemaker study (2014-2015)
D - Research funding (departmental or institutional).- St Jude Medical : Pacemaker (2013-2014-2015)
Manolis Athanasios John A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Abbott : Hypertension, (2013-2014-2015)
- Menarini : hypertension, heart failure (2013-2014-2015)
- Bayer AG : atrial fibrillation (2014-2015)
- Servier : hypertension (2014-2015)
- Berlin Chemie AG : hypertension (2014-2015)
- Ferrer Internacional : hypertension (2014-2015)
- Recordati International : hypertension (2014-2015)
D - Research funding (departmental or institutional).- Bayer : AF (2013-2014-2015)
- Boehringer-Ingelheim : AF (2013-2014-2015)
- GlaxoSmithKline : Coronary Heart Diseaese (2013-2014-2015)
- Servier : Heart Failure (2013-2014-2015)
- Amgen : hyperlipidemia (2014-2015)
- Sanofi Aventis : hyperlipidemia (2014-2015)
Marinskis Germanas Nothing to be declared (2013-2014)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- BackBeat Medical : Pacemaker (2015)
Mikhaylov Evgeny A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Medtronic : Medical devices (2013-2014-2015)
- Biosense Webster : Medical devices (2013-2014-2015)
27/08/2015
Guidelines on Sudden Cardiac Death 2015 (TF07) - Document Reviewers
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
27/46
Mikhaylov Evgeny B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Biosense Webster : Medical devices (2013-2014-2015)
Mirrakhimov Aibek Nothing to be declared (2013-2014-2015)
Morais Joao A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- JaBA Recordati : Lipids and Hypertension (2013)
- Merck Sharp & Dohme : Lpids (2013)
- Bayer Healthcare : Rivaroxaban (2013)
- Astra Zeneca : Ticagrelor (2013)
- Daiichi Sankyo : anticoagulants (2014)
- Merck Sharp & Dohme : lipids (2014)
- Boehringer-Ingelheim : anticoagulants (2014-2015)
- Pfizer : anticoagulants (2014-2015)
- Bayer Healthcare : anticoagulants (2014-2015)
- BMS : anticoagulants (2014-2015)
- Astra Zeneca : antiplatelets (2014-2015)
- Eli Lilly C : antiplatelets (2014-2015)
- Daiichi Sankyo : antiplatelets (2015)
- Merck Sharp & Dohme : lipids and antiplatelets and diabetes (2015)
E - Research funding (personal).- Servier : ivabradin (2013)
- Servier : ischemic heart disease (2014)
Moreno Planas Javier A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Medtronic : Defibrillators (2013)
- Sorin Group : Defibrillators (2013-2014-2015)
27/08/2015
Guidelines on Sudden Cardiac Death 2015 (TF07) - Document Reviewers
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
28/46
Moreno Planas Javier - Boston Scientific : Defibrillators, EP catheters (2013-2014-2015)
- St Jude Medical : Defibrillators, EP catheters (2013-2014-2015)
- Biotronik : Defibrillators, EP catheters (2013-2014-2015)
- Biosense Webster : EP catheters (2013-2014-2015)
- Medtronic : Defibrillators, EP catheters (2014-2015)
Morgado Francisco Bello A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Sorin Group : CRT (2013)
- St Jude Medical : CRt (2013-2014-2015)
- Bayer : NOAC (2013-2014-2015)
- Pfizer : NOAC (2014-2015)
Parkhomenko Alexander A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : trimetazidin, rivaroxaban, ticagrelor (2013-2014)
- BHFZ : corvitin (2015)
- Bayer Healthcare : rivaroxaban (2015)
- Astra Zeneca : ticagrelor (2015)
- Servier : trimetazidine (2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer : rivaroxabane (2013-2014)
C - Receipt of royalties for intellectual property.- BHFZ : corvitine (2013-2014)
D - Research funding (departmental or institutional).- European Research Foundation FP7 : biomarkers (2015)
Piepoli Massimo Francesco Nothing to be declared (2013-2014-2015)
Piot Olivier A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- BMS : antithrombotic (2013)
- St Jude Medical : IPG, ICD (2013)
27/08/2015
Guidelines on Sudden Cardiac Death 2015 (TF07) - Document Reviewers
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
29/46
Piot Olivier - Medtronic : IPG, ICD, Ablation catheter (2013)
- Bristol Myers Squibb : DOA (2014)
- Medtronic : IPG, ICD, Ablation (2014)
- St Jude Medical : IPG, ICD, Ablation (2014)
- Bayer : DOA (2015)
- BMS Pfizer : DOA (2015)
- Medtronic : IPG/ICD (2015)
- Sorin Group : IPG/ICD (2015)
- saint Jude medical : IPG/ICD (2015)
E - Research funding (personal).- St Jude Medical : CRT (2013)
Piruzyan Armen A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer : NOACs-Rivaroxaban (2013-2014)
- Takeda Pharmaceuticals : Bisoprolol (2013-2014-2015)
- Servier : Ivabradine,Triplexam (2013-2014-2015)
- Krka Pharma : Statines (2013-2014-2015)
Puljevic Davor Nothing to be declared (2013-2014-2015)
Raducan Aurica Nothing to be declared (2013-2014-2015)
Roithinger Franz Xaver A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer : Anticoagulation (2013-2014-2015)
- Boehringer-Ingelheim : Anticoagulation (2013-2014-2015)
- Daiichi Sankyo : Anticoagulation (2013-2014-2015)
- Astra Zeneca : Platelet inhibition (2013-2014-2015)
27/08/2015
Guidelines on Sudden Cardiac Death 2015 (TF07) - Document Reviewers
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
30/46
Roithinger Franz Xaver B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bristol Myers Squibb : Anticoagulation (2013-2014-2015)
- Biotronik : Device Therapy (2013-2014-2015)
- Biosense Webster : Electrophysiology (2013-2014-2015)
D - Research funding (departmental or institutional).- Astra Zeneca : Platelet inhibition (2013-2014-2015)
Rutten Frans Hendrik D - Research funding (departmental or institutional).- Boehringer-Ingelheim : anticoagulants (2013)
- Boehringer-Ingelheim : Atrial fibrillation (2014-2015)
Sammut Mark Adrian Nothing to be declared (2013-2014-2015)
Shalganov Tchavdar A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Pfizer : apixaban (2013-2014)
- Actavis : ECG training of family physicians (2013-2014)
- Bayer : rivaroxaban (2014-2015)
Sredniawa Beata A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boehringer-Ingelheim : Pradaxa (2013-2014-2015)
- Adamed : Nebilenin (2014)
- Bayer : Xarelto (2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Adamed : Nebilenin (2013-2014)
D - Research funding (departmental or institutional).- Zoll Medical : Therapeutic Hypothermia (2013-2014-2015)
E - Research funding (personal).- Zoll Medical : Therapeutic Hypothermia (2013-2014-2015)
Sticherling Christian A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bard : Ablation therapy (2013-2014)
- Bristol Myers Squibb : Anticoagulants, atrial fibrillation (2013-2014)
27/08/2015
Guidelines on Sudden Cardiac Death 2015 (TF07) - Document Reviewers
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
31/46
Sticherling Christian - Bayer : Anticoagulants, atrial fibrillation (2013-2014-2015)
- Medtronic : Defibrillators, Pacemaker (2013-2014-2015)
- Sorin Group : Defibrillators, Pacemaker (2013-2014-2015)
- Biotronik : Defibrillators, Pacemaker, (2013-2014-2015)
- Boehringer-Ingelheim : anticoagulants, atrial fibrillation (2015)
- Daiichi Sankyo : anticoagulants, atrial fibrillation (2015)
- Boston Scientific : Defibrillator, Pacemaker (2015)
D - Research funding (departmental or institutional).- Biosense Webster : Atrial fibrillation (2013-2014-2015)
- Biotronik : CRT (2013-2014-2015)
Tande Pal Morten Nothing to be declared (2014-2015)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- St Jude Medical : Ablation technology (2013)
Vatasescu Radu-Gabriel Nothing to be declared (2013-2014-2015)
Zamorano Gomez Jose Luis
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Daiichii : Atrial Fib (2013)
- Merck Sharp & Dohme : Lipid Lowering (2013)
- Philips : 3D echo (2014)
- Toshiba medical imaging : fusion imaging 3D echo CT (2014)
- Astra Zeneca : Speaker fee for 1 talk in 2014 (2014)
- MSD : CV risk factors (2014-2015)
- Abbott : Lecturing (2015)
- Astra Zeneca : Lecturing (2015)
- Pfizer : Lecturing (2015)
27/08/2015
Guidelines on Sudden Cardiac Death 2015 (TF07) - Document Reviewers
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
32/46
Zamorano Gomez Jose Luis
- Sorin Group : Respicardia echo protocol (2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- European Research FP7 : CV Imaging (2013)
- Servier : Imaging in ISchemic patients (2013)
- Siemens Healthcare : 3d echo software and free style echo (2014-2015)
- Toshiba medical imaging : Fusion Imaging (2015)
C - Receipt of royalties for intellectual property.- Springer : ESC Textbook of CV Imaging (2013)
D - Research funding (departmental or institutional).- Amgen : Clinical trial (2014-2015)
- Novartis : Clinical trial (2014-2015)
- Ikaria : Clinical trial (2014-2015)
Zannad Faiez A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Biotronik : heart failure (2013)
- Novartis : aliskiren (2013-2014)
- Takeda Pharmaceuticals : diabetes (2013-2014-2015)
- Pfizer : eplerenone (2013-2014-2015)
- Boston Scientific : heart failure (2013-2014-2015)
- Servier : heart failure (2013-2014-2015)
- Bayer Healthcare : heart failure (2013-2014-2015)
- Janssen-Cilag : Rivaroxaban (2013-2014-2015)
- Resmed : sleep apena (2013-2014-2015)
- Astra Zeneca : cardiovascular (2014-2015)
- Merck Sharp & Dohme : diabetes (2014-2015)
27/08/2015
Guidelines on Sudden Cardiac Death 2015 (TF07) - Document Reviewers
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
33/46
Zannad Faiez - Mitsubishi : heart failure (2014-2015)
- Air liquide : oxygen (2014-2015)
- Eli Lilly : heart failure (2015)
- Novartis : heart failure (2015)
- Quantum Genomics : Heart Failure (2015)
- Stealth Peptide : Heart failure (2015)
- Relypsa : patiromer (2015)
- ZS Pharma : ZS9 (2015)
D - Research funding (departmental or institutional).- Roche Diagnostics : biomarker (2013-2014-2015)
E - Research funding (personal).- Roche Diagnostics : biomarker (2013)
Zeppenfeld Katja A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- St Jude Medical : 3D mapping systems (2013)
D - Research funding (departmental or institutional).- Boston Scientific : ICD, pacemaker (2013-2014-2015)
- Medtronic : ICD, pacemaker (2013-2014-2015)
- Biotronic : ICD, pacemaker (2013-2014-2015)
- Edwards Lifesciences : percutaneous valve (2013-2014-2015)
27/08/2015
Guidelines on Sudden Cardiac Death 2015 (TF07) - Document Reviewers
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
34/46
Aboyans Victor Nothing to be declared (2013)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Antithrombotics (2014)
- Sanofi Aventis : Hyperlipidemia (2014)
- Boehringer-Ingelheim : Oral anticoagulation (2014)
- Pfizer/BMS alliance : Oral anticoagulation (2014)
- Novartis : Hypertension (2014-2015)
- Bayer Healthcare : Oral anticoagulation (2014-2015)
- Merck Sharp & Dohme : Antithrombotics (2015)
Achenbach Stephan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer : Anticoagulation (2013)
- Behring : Anticoagulation (2013)
- Astra Zeneca : Antiplatelet Therapy (2013)
- Abbott : Coronary Intervention (2013)
- Siemens Healthcare : CT (2013)
- Servier : Imaging (2013)
- Guerbet : Imaging (2013)
D - Research funding (departmental or institutional).- Abbott : Coronary Intervention (2013-2014)
- Siemens Healthcare : Imaging (2013-2015)
Agewall Stefan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Böhringer Ingelheim : Anticoagulatn treatment (2013)
- Roche Diagnostics : Cardiac markers (2013)
- Orion : Heart failure (2013)
27/08/2015
Committee for Practice Guidelines 2014-2016 - MEMBERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
35/46
Agewall Stefan - Pfizer : Lipids (2013)
- Sanofi Aventis : Lipids (2013)
- Siemens Healthcare : Markers (2013)
- Astra Zeneca : Platelet inhibition (2013-2014-2015)
- Thermo Fischer Scientific : Cardiac markers (2014-2015)
Badimon Lina A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : cardiovascular (2013)
- Sanofi Aventis : cardiovascular (2013)
- MSD-España : Lipids (2014)
- Sanofi Aventis : lipids (2014-2015)
- Burson Masteller : nutrition (2014-2015)
- Astra Zeneca : thrombosis (2014-2015)
D - Research funding (departmental or institutional).- Astrazeneca : thrombosis (2014-2015)
Baron Esquivias Gonzalo A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer : Anticoagulation (2013-2014-2015)
- Boehringer-Ingelheim : Anticoagulation (2013-2014-2015)
- Daiichi Sankyo : Anticoagulation (2013-2014-2015)
- Pfizer : Anticoagulation (2013-2014-2015)
- Menarini : Ischemic disease (2015)
- Laboratorios Rovi : Ivabradine (2015)
D - Research funding (departmental or institutional).- Biotronik : Vasovagal syncope & Pacing (2013)
- Bayer : Anticoagulation (2015)
27/08/2015
Committee for Practice Guidelines 2014-2016 - MEMBERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
36/46
Baumgartner Helmut A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Actelion : Bosentan and Macicentan for PAH treatment in congenital heart disease (2013-2014-2015)
- St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) (2013-2014-2015)
- Abbott : transcather mitral valve repair (Mitraclip) (2013-2014-2015)
- Edwards Lifesciences : transcatheter valve implantation (2013-2014-2015)
- Direct Flow Medical : transcatheter valve implantation (2013-2014-2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Actelion : Bosentan for PAH treatment in congenital heart disease (2013-2014-2015)
- St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) (2013-2014-2015)
- Abbott : transcather mitral valve repair (Mitraclip) (2013-2014-2015)
- Edwards Lifesciences : transcatheter valve implantation (2013-2014-2015)
- Direct Flow Medical : transcatheter valve implantation (2013-2014-2015)
Bax Jeroen Nothing to be declared (2014-2015)
D - Research funding (departmental or institutional).- Servier : Farma (2013)
- Edwards Lifesciences : Heart Valves (2013)
- GE Healthcare : Imaging (2013)
- Lantheus Inc : Imaging (2013)
- Boston Scientific : Pacing (2013)
- Medtronic : Pacing (2013)
- St Jude Medical : Pacing (2013)
- Biotronik : Pacing (2013)
Bueno Hector A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- BMS/Pfizer : Apixaban (2013)
27/08/2015
Committee for Practice Guidelines 2014-2016 - MEMBERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
37/46
Bueno Hector - Roche Pharma : Dalcetrapib (2013)
- Novartis : Relaxin (2013)
- Bayer Healthcare : Aspirin, rivaroxaban (2013-2014-2015)
- Sanofi Aventis : Clopidogrel (2013-2014-2015)
- Daiichi Sankyo : Prasugrel (2013-2014-2015)
- Eli Lilly : Prasugrel (2013-2014-2015)
- Astra Zeneca : Ticagrelor (2013-2014-2015)
- Novartis : Serelaxin (2014)
- Pfizer : Apixaban (2014-2015)
- Bristol Myers Squibb : Apixaban (2014-2015)
- Servier : ivabradine (2014-2015)
- Menarini : Ranolazine (2014-2015)
- Abbott : Absorb stent (2015)
- Novartis : Serelaxin, ACZ696 (2015)
- Ferrer Internacional : Trinomia (polypill) (2015)
D - Research funding (departmental or institutional).- Astra Zeneca : Funding of TAN-SNIP observational study. No drugs involved (2015)
E - Research funding (personal).- Astra Zeneca : Ticagrelor (2013-2014-2015)
Carerj Scipione Nothing to be declared (2013-2014-2015)
Erol Cetin A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Hypertension (2013-2014-2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Menarini : Hypertension (2013-2014-2015)
27/08/2015
Committee for Practice Guidelines 2014-2016 - MEMBERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
38/46
Fitzsimons Donna Nothing to be declared (2013-2015)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Amgen : FH Tratment options (2014)
Gaemperli Oliver Nothing to be declared (2013)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Biosensors : Stents (2014)
- Biosensors : Axxess Bifurcation Stent (2015)
- Abbott Vascular : MitraClip (2015)
- Biosensors : Travel Grant to AsiaPCR 2015 (2015)
Kirchhof Paulus A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Otsuka Pharmaceuticals Development and Commercialization (consultancy) : cardiovascular (2013)
- Boehringer-Ingelheim : cardiovascular (2013-2014-2015)
- Daiichi Sankyo : cardiovascular (2013-2014-2015)
- Medtronic : cardiovascular (2013-2014-2015)
- Pfizer : cardiovascular (2013-2014-2015)
- St Jude Medical : cardiovascular (2013-2014-2015)
- Sanofi Aventis : cardiovascular (2013-2014-2015)
- Meda pharma : cardiovascular (2013-2014-2015)
- Bristol Myers Squibb : cardiovascular (2013-2014-2015)
- Merck Sharp & Dohme : cardiovascular (2013-2014-2015)
- Medscape : cardiovascular (2014-2015)
- Bayer Healthcare : cardiovascular (2015)
- Correvio : cardiovascular (2015)
- Remedica : cardiovascular (2015)
27/08/2015
Committee for Practice Guidelines 2014-2016 - MEMBERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
39/46
Kirchhof Paulus B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Boehringer-Ingelheim : cardiovascular (2013)
- Bayer Healthcare : cardiovascular (2013)
- Gilead : cardiovascular (2013)
- BMS / Pfizer alliance : cardiovascular (2013)
D - Research funding (departmental or institutional).- St Jude Medical : cardiovascular (2013-2014-2015)
- Sanofi Aventis : cardiovascular (2013-2014-2015)
- Meda pharma : cardiovascular (2013-2014-2015)
- Daiichi Sankyo : cardiovascular (2014-2015)
- British Heart Foundation : cardiovascular (2014-2015)
- BMS / Pfizer alliance : cardiovascular (2014-2015)
- Leducq Foundation : cardiovascular (2014-2015)
- European Union FP7 : cardiovascular (2014-2015)
- European Union horizon2020 : cardiovascular (2014-2015)
- German Centre for Heart Research (DZHK, funded by German Ministry of Education and Research) : cardiovascular (2014-2015)
Kolh Philippe H A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- B.Braun : Surgical instruments (2013-2014)
- Astra Zeneca : Antiplatelet agents (2013-2014-2015)
D - Research funding (departmental or institutional).- St Jude Medical : Cardiac valves (2013)
- Boston Scientific : Coronary stents (2013)
- Siemens Healthcare : Medical imaging (2013)
- Johnson & Johnson : Thoracoscopic devices (2013)
27/08/2015
Committee for Practice Guidelines 2014-2016 - MEMBERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
40/46
Kolh Philippe H - Edwards Lifesciences : Cardiac valves (2013-2014-2015)
- Medtronic : Cardiac valves (2013-2014-2015)
Lancellotti Patrizio A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Servier : Heart Failure (2013)
- Abbott : MitraClip (2013)
- Menarini : nebivolol (2014)
- St Jude Medical : Heart Failure (2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astrazeneca : Dyslipidemia (2013)
- Boston Scientific : CRT (2014)
- Servier : procoralan (2014)
- Daiichi Sankyo : Teaching course on imaging (2015)
D - Research funding (departmental or institutional).- Actelion : Pulmonary Hypertension (2013)
Lip Gregory Y H A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astellas : atrial fibrillation, thrombosis (2013)
- Biotronik : atrial fibrillation (2013-2014-2015)
- Boehringer-Ingelheim : atrial fibrillation, thrombosis (2013-2014-2015)
- Daiichi Sankyo : atrial fibrillation, thrombosis (2013-2014-2015)
- Pfizer : atrial fibrillation, thrombosis (2013-2014-2015)
- Bayer Healthcare : atrial fibrillation, thrombosis (2013-2014-2015)
- Bristol Myers Squibb : atrial fibrillation, thrombosis (2013-2014-2015)
- Medtronic : atrial fibrillation (2014-2015)
- Roche Diagnostics : anticoagulation (2015)
27/08/2015
Committee for Practice Guidelines 2014-2016 - MEMBERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
41/46
Lip Gregory Y H D - Research funding (departmental or institutional).- Bayer : atrial fibrillation, thrombosis (2013)
- Daiichi Sankyo : atrial fibrillation, thrombosis (2014-2015)
Nihoyannopoulos Petros Nothing to be declared (2014-2015)
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- GSK : Consultant for Imaging studies (2013)
Piepoli Massimo Francesco Nothing to be declared (2013-2014-2015)
Ponikowski Piotr A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer : anticoagulant (2013)
- Bristol Myers Squibb : anticoagulant (2013)
- ROSCHE : diabetes (2013)
- Boehringer-Ingelheim : anticoagulant (2013-2014)
- Respicardia : anticoagulant (2013-2014)
- Johnson & Johnson : heart failure (2013-2014)
- Pfizer : heart failure, anticoagulant (2013-2014)
- Abbott Vascular : devices (2013-2014-2015)
- Novartis : heart failure (2013-2014-2015)
- Cardiorentis : heart failure (2013-2014-2015)
- Bayer Healthcare : heart failure (2013-2014-2015)
- Vifor Pharma ltd : heart failure (2013-2014-2015)
- CIBIEM : heart failure (2013-2014-2015)
- Servier : heart failure, coronary artery disease (2013-2014-2015)
- Amgen : heart failure, lipids (2013-2014-2015)
- MSD : lipids (2014)
27/08/2015
Committee for Practice Guidelines 2014-2016 - MEMBERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
42/46
Ponikowski Piotr - Astra Zeneca : acute coronary syndrome (2014-2015)
- Boehringer-Ingelheim : anticoagulant, diabetes (2015)
- Respicardia : devices (2015)
- BioControl : devices (2015)
- DC Device : devices (2015)
- Celladon : heart failure (2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Vifor Pharma ltd : heart failure (2014)
- MSD : lipids (2014)
- Astra Zeneca : acute coronary syndrome (2014-2015)
- Respicardia : anticoagulant (2014-2015)
- Novartis : heart failure (2014-2015)
- Cardiorentis : heart failure (2014-2015)
- Bayer Healthcare : heart failure (2014-2015)
- CIBIEM : heart failure (2014-2015)
- Servier : heart failure, coronary artery disease (2014-2015)
- Amgen : heart failure, lipids (2014-2015)
- BioControl : devices (2015)
- DC Device : devices (2015)
- Celladon : heart failure (2015)
D - Research funding (departmental or institutional).- Vifor Pharma ltd : heart failure (2013)
- Singulex : biomarkers (2015)
27/08/2015
Committee for Practice Guidelines 2014-2016 - MEMBERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
43/46
Roffi Marco A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Daiichi Sankyo : antiplatelet therapy (2013)
- Lilly : antiplatelet therapy (2013)
- Astra Zeneca : antipletelet therapy (2013)
- Johnson & Johnson : coronary catheters (2014)
D - Research funding (departmental or institutional).- Biosensors : devices (2013-2014-2015)
- Boston Scientific : devices (2013-2014-2015)
- Medtronic : devices (2013-2014-2015)
- Biotronik : devices (2013-2014-2015)
- Abbott Vascular : devices (2013-2014-2015)
Torbicki Adam A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bristol Myers Squibb : Pulmonary arterial hypertension (2013-2014-2015)
- GlaxoSmithKline : pulmonary arterial hypertension - ambrisentan (2013-2014-2015)
- Lilly : pulmonary arterial hypertension - ambrisentan (2013-2014-2015)
- Actelion : pulmonary arterial hypertension - macitentan, selexipag (2013-2014-2015)
- Bayer Healthcare : pulmonary arterial hypertention - iloprost, riociguat, VTE - xarelto (2013-2014-2015)
- AOP Orphan Pharmaceuticals : pulmonary arterial hypertension (2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Bayer Healthcare : Pulmonary hypertension (2013-2014-2015)
Vaz Carneiro Antonio Nothing to be declared (2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- AbbVie : Oncology (2013-2014)
Windecker Stephan A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Astra Zeneca : Antiplatelet drug (2013)
- Eli Lilly : Antiplatelet drug (2013)
27/08/2015
Committee for Practice Guidelines 2014-2016 - MEMBERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
44/46
Windecker Stephan - Abbott : Stent (2013)
- Medtronic : Stent (2013)
- Biotronik : Stent (2013)
- Astra Zeneca : Antiplatelet therapy (2014-2015)
- Eli Lilly : Antiplatelet therapy (2014-2015)
- Bayer Healthcare : Antithrombotic drug (2014-2015)
- Abbott : Stent and Heartvalvetherapy (2014-2015)
- Biosensors : Stents (2014-2015)
- Boston Scientific : Stents (2014-2015)
- Medtronic : TAVI, Stent (2015)
- Edwards Lifesciences : Transcatheter heart valves (2015)
D - Research funding (departmental or institutional).- St Jude Medical : OCT (2013-2014-2015)
- Biotronik : Stent (2013-2014-2015)
- Medtronic : Stent and Heartvalves (2014)
- Medicines Company : Antithrombotic therapy (2014-2015)
- Johnson & Johnson : Catheters (2014-2015)
- Edwards Lifesciences : Heartvalves (2014-2015)
- Abbott : Stent (2014-2015)
- Boston Scientific : Stent and Heartvalves (2014-2015)
Zamorano Gomez Jose Luis
A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- Daiichii : Atrial Fib (2013)
- Merck Sharp & Dohme : Lipid Lowering (2013)
27/08/2015
Committee for Practice Guidelines 2014-2016 - MEMBERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
45/46
Zamorano Gomez Jose Luis
- Philips : 3D echo (2014)
- Toshiba medical imaging : fusion imaging 3D echo CT (2014)
- Astra Zeneca : Speaker fee for 1 talk in 2014 (2014)
- MSD : CV risk factors (2014-2015)
- Abbott : Lecturing (2015)
- Astra Zeneca : Lecturing (2015)
- Pfizer : Lecturing (2015)
- Sorin Group : Respicardia echo protocol (2015)
B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.- European Research FP7 : CV Imaging (2013)
- Servier : Imaging in ISchemic patients (2013)
- Siemens Healthcare : 3d echo software and free style echo (2014-2015)
- Toshiba medical imaging : Fusion Imaging (2015)
C - Receipt of royalties for intellectual property.- Springer : ESC Textbook of CV Imaging (2013)
D - Research funding (departmental or institutional).- Amgen : Clinical trial (2014-2015)
- Novartis : Clinical trial (2014-2015)
- Ikaria : Clinical trial (2014-2015)
27/08/2015
Committee for Practice Guidelines 2014-2016 - MEMBERS
Expert Type of Relationship with Industry
For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.
46/46